ANN ARBOR, Mich., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration. In addition, Adeona also announced the appointment of the zinc research pioneer, Ananda S. Prasad, M.D., Ph.D., to the Company's Scientific Advisory Board.
"I am pleased to join the Scientific Advisory Board of Adeona, a company leading the development of zinc-based therapies addressing diseases in the elderly," said Ananda S. Prasad, M.D., Ph.D. "I look forward to providing guidance as Adeona moves their promising zinc-based product candidates through development."
Zinc for Prevention of Infection in the Elderly
Adeona has entered into an agreement with Dr. Prasad that provides the Company with access to clinical data from a 50 patient, 12-month, randomized, double-blind, placebo-controlled clinical trial that evaluated the prevention of infection in patients age 55 to 87 who were treated with an oral zinc therapy (45 mg elemental zinc per day away from food) or matching placebo. The clinical trial was conducted by Dr. Prasad and co-investigators. The primary endpoint of the clinical trial was the rate of infections between the placebo and zinc treated groups. The results at 12 months demonstrated a 67% reduction in the incidence of infection between the two groups (88 infections in the placebo group versus 29 infections in the zinc trea